Literature DB >> 1696776

Immune release of histamine and other lipid mediators from guinea-pig isolated kidney: antagonism by BN-52021.

F Berti1, G Rossoni, P Braquet.   

Abstract

The ability of a specific PAF-receptor antagonist, BN-52021, to control the release of mediators of anaphylaxis from actively sensitized (ovalbumin) guinea-pig has been investigated "in vitro". BN-52021 perfused through the kidney at different molar concentrations (1 x 10(-4)-1 x 10(-5)-1 x 10(-6] prior to antigen challenge neither modified the basal values of perfusion pressure nor stimulated mediator release from the organ. On the contrary, the compound antagonized in a concentration dependent way both vasoconstriction of the renal vessels and the increase in the perfusate of histamine, TXB2 and SRS-A due to antigenic shock. The antagonistic activity of BN-52021 was very consistent at 1 x 10(-4) M at which concentration the immunological release of histamine and TXB2 was reduced by 75%. The beneficial effect of BN-52021 in experimental anaphylaxis of the kidney may have some therapeutic implications principally in those pathological conditions where an abnormal increase of renal histamine and other mediators may compromise the haemodynamic function of this organ.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1696776     DOI: 10.1007/bf01966291

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  19 in total

1.  A laminar flow superfusion technique with much increased sensitivity for the detection of smooth muscle-stimulating substances.

Authors:  S H Ferreira; F De Souza Costa
Journal:  Eur J Pharmacol       Date:  1976-10       Impact factor: 4.432

2.  Renal anaphylaxis. I. Antigen-initiated responses from isolated perfused rat kidney.

Authors:  E Pirotzky; G Pintos-Morell; C Burtin; J Boudet; J Bidault; J Benveniste
Journal:  Kidney Int       Date:  1987-08       Impact factor: 10.612

3.  The PAF-acether receptor antagonist BN-52021 inhibits mediator release during guinea-pig active lung anaphylaxis.

Authors:  F Berti; G Galli; F Magni; G Rossoni; L Villa; L Puglisi; R Pasargiklian; P Braquet
Journal:  Pharmacol Res Commun       Date:  1988-12

4.  Paf-acether (platelet-activating factor) and interleukin-1-like cytokine production by lipopolysaccharide-stimulated glomeruli.

Authors:  G P Morell; E Pirotzky; D Erard; R M Desmottes; J Bidault; C Damais; J Benveniste
Journal:  Clin Immunol Immunopathol       Date:  1988-03

5.  Determination of histamine in small biopsies and histological sections.

Authors:  L Juhlin
Journal:  Acta Physiol Scand       Date:  1967-09

6.  Release of additional factors in anaphylaxis and its antagonism by anti-inflammatory drugs.

Authors:  P J Piper; J R Vane
Journal:  Nature       Date:  1969-07-05       Impact factor: 49.962

7.  Mechanisms of action of hisamine and histamine antagonists on the glomerular microcirculation in the rat.

Authors:  I Ichikawa; B M Brenner
Journal:  Circ Res       Date:  1979-12       Impact factor: 17.367

8.  Release of thromboxane B2 and leukotriene C4 and reduction in renal perfusion in experimental anaphylactic reaction of isolated guinea pig kidney.

Authors:  E S Assem; N A Abdullah
Journal:  Int Arch Allergy Appl Immunol       Date:  1987

9.  Release of platelet-activating factor and histamine. I. Effect of immune complexes, complement and neutrophils on human and rabbit mastocytes and basophils.

Authors:  G Camussi; J M Mencia-Huerta; J Benveniste
Journal:  Immunology       Date:  1977-10       Impact factor: 7.397

10.  Biosynthesis of platelet-activating factor. VI. Precursor of platelet-activating factor and acetyltransferase activity in isolated rat kidney cells.

Authors:  E Pirotzky; E Ninio; J Bidault; A Pfister; J Benveniste
Journal:  Lab Invest       Date:  1984-11       Impact factor: 5.662

View more
  1 in total

Review 1.  PAF. A review of its effects, antagonists and possible future clinical implications (Part II).

Authors:  M Koltai; D Hosford; P Guinot; A Esanu; P Braquet
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.